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AIM: Eurycomanone is a cytotoxic compound found in Eurycoma longifolia Jack.
Previous studies had noted the cytotoxic effect against various cancer cell lines.  The
aim of this study is to investigate the cytotoxicity against human cervical carcinoma
cells and the mode of action.
METHODS: The cytotoxicity of eurycomanone was evaluated using methylene blue
staining assay and the mode of cell death was detected by Hoechst 33258 nuclear
staining, TUNEL assay and flow cytometry with Annexin-V/propidium iodide double
staining.  The protein expression of p53, E6, E6-AP, Bax and Bcl-2 were studied by
Western blotting.  Immunostaining assay was used to confirm the up-regulation of p53
and Bax in cancer cells.
RESULTS: The findings suggested that eurycomanone was cytotoxic on cancerous
cells (CaOv-3, HeLa, HepG2, HM3KO, MCF-7) and less toxic on normal cells (MDBK,
Vero).  Furthermore, various methods proved that apoptosis was the mode of death in
eurycomanone-treated cervical cancer HeLa cells.  The characteristics of apoptosis
including chromatin condensation, DNA fragmentation and apoptotic bodies were
found following eurycomanone treatment.  This study also found that apoptotic proc-
ess triggered by eurycomanone involved the up-regulation of p53 tumor suppressor
protein.  The up-regulation of p53 was followed by the increasing of pro-apoptotic Bax
and decreasing of anti-apoptotic Bcl-2.  However, eurycomanone did not affect the E6
and E6-AP protein expression.
CONCLUSION: The data suggest that eurycomanone was cytotoxic on HeLa cells by
inducing apoptosis through the up-regulation of p53 and Bax, and down-regulation of
Bcl-2, independently of functional E6 and E6-AP activity.
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Introduction
Cervical cancer is an important health problem worldwide,
being the second most common cancer among women and
first ranking in many developing countries [1].  In Malaysia,
cancer of the cervix was the second most common cancer
among women.  The National Cancer Registry in 2004
reported the incidence of cervical cancer was 12.9% of total
female cancers.  There were a total of 1,557 cases of cancer
cervix, with an ASR of 19.7 per 100,000 populations [2].
Specific types of human papillomavirus (HPV2), mainly
types 16 and 18, have been identified as causative agents of
at least 90% cervical cancer and are also linked to more than
50% of other anogenital cancers [3,4].  Cervical carcinoma is
initiated by infection with a high risk HPV, usually HPV type
16 (HPV16) or HPV18,  and gene transfer studies have identi-
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fied the E6 and E7 genes as the major HPV oncogenes [5].
The expression of p53 is very low in cervical cancer cells
[6].  The E6 and the E7 proteins modulate cellular proteins
that regulate the cell cycle [7,8].  In cooperation with the
cellular proteins E6-AP, the E6 protein binds to the tumor
suppressor protein p53, and targets it for accelerated
degradation.  However, in response to DNA damage stress,
p53 is stabilized and induced to exert its various cellular
responses including apoptosis [9,10].
Eurycoma longifolia Jack is one of the popular folk medi-
cines of South East Asia including Myanmar, Indochina,
Thailand, Laos, Cambodia and Malaysia [11].  E. longifolia is
identified locally as Tongkat Ali in Malaysia, Pasakbumi or
Bidara Pahit in Indonesia, Ian-don in Thailand and “Cay ba
binh” in Vietnam translated as a tree which cures hundreds
of diseases [12].
Several classes of compounds have been isolated and
identified, including quassinoids [12-22], canthin-6-one
alkaloids [12,23], β-carboline alkaloids [11,12], triterpene
tirucallane type [18], squalene derivatives [24] and
biphenylneolignan [25].
Previous study of methanolic extract showed induction of
apoptosis in human breast cancer MCF-7 cell lines via
decreasing of Bcl-2 expression [26].  Eurycomanone isolated
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from E. longifolia was also proven to inhibit the growth of
MCF-7 cells by triggering apoptosis through down-regulation
of the anti-apoptotic protein Bcl-2.  It is relatively non-toxic
in non-cancerous breast cell lines (MCF-10A)[27].
The objective of this study is to evaluate the anti-
proliferative effect of eurycomanone and the mechanism of
cell death in human cervical carcinoma HeLa cells.
Materials and Methods
Compound extraction
Eurycomanone (Figure 1) was extracted from the root of E.
longifolia as previously described [13].  The root of the plant
(1350 g) was dried, ground and extracted with methanol.  The
methanol extract was then concentrated to dryness.  A
suspension of the dry extract (500 g) in water was separated
with diethyl ether using separating funnel.  The water
fraction was then separated with n-buthanol saturated with
water.  The buthanol layer was then evaporated to dryness,
and the dry buthanol fraction (20 g) was subjected to column
chromatography over silica gel using a mixture of ethyl
acetate-ethanol-water (100:10:1) as the mobile phase.  The
white crystal (0.16 g) was found and identified as eurycoma-
none by comparison of NMR spectral data with published
value [12,28].
Cell culture
All cell lines (CaOv-3, HeLa, HepG2, HM3KO, MCF-7, Vero,
and MDBK) were obtained from American Type Culture
Collection (Rockville, MD, USA).  The cell lines were main-
tained in DMEM medium supplemented with 5% FBS and 1%
penicillin-streptomycin.  The cells were grown at 37°C in
humidified atmosphere of 5% CO2.
Cell proliferation assay
The anti-proliferative effect of eurycomanone on cancer
cells was evaluated by determining the IC50 values for the
above mentioned cell lines as previously described [29].
Logarithmically growing cells were seeded at a density of 5 ×
103 cells/well into 96-well plates and allowed to adhere for 24
h at 37°C.  Then the seeding medium was discarded and
replaced with fresh medium containing varying concentra-
tions of eurycomanone.  The cells were maintained for 3
days and the anti-proliferative activity of eurycomanone was
determined using the methylene blue staining.  Glutaralde-
hyde was added to each well to a final concentration of 2.5%
(v/v).  After 15-min incubation, the cells were washed with
0.15 M NaCl.  The cells were then stained with 0.1 ml of 0.05%
methylene blue solution for 15 min.  The excess dye was
washed out and 0.2 ml of 0.33 M HCl was added into each
well.  The absorbance was read at 660 nm.
TUNEL assay
DNA fragmentation, one of the characteristics of apoptotic
cells, was examined by TdT-mediated dUTP nick end labeling
(TUNEL) assay.   HeLa cells were seeded onto a poly-L-lysine
Figure 1: Chemical structure of eurycomanone
slide in a petri dish.  After 24 h adherence, the cells were
incubated without or with eurycomanone (5 µM) for 24 and 72
h.  Tamoxifen (21.5 µM) was used as positive control.  At the
end of the treatment, the cells were fixed with 4% methanol-
free paraformaldehyde in PBS at 4°C for 30 min and then
washed with PBS for further analysis.  The cells were stained
with fluorescent TUNEL assay kit (Promega, Madison, WI,
USA) according to the manufacturer’s instruction.  This
assay detects apoptotic cells when visualized through the
fluorescence microscope (Leica, Vertrieb Deutschland,
Solms, Germany).
Nuclear staining assay
Staining with Hoechst 33258 was performed according to
the method previously described [30].  HeLa cells were
treated with 5 µM of eurycomanone for 24 h, and then the
cells were washed with PBS and fixed with 4% methanol-free
paraformaldehyde for 30 min at 4°C.  The fixed cells were
washed with PBS and stained with Hoechst 33258 (Sigma, St.
Louis, MO, USA) at a final concentration of 30 µg/ml.  The
slides were observed under fluorescence microscope (Leica).
Flow cytometry analysis
The number of apoptotic cell death induced by eurycoma-
none was measured by flow cytometry using the
APOPTESTTM-FITC kit according to manufacturer’s protocol
(DakoCytomation, Glostrup, Denmark).  The treated and
untreated HeLa cells were harvested and washed with cold
PBS.  An aliquot (105 cells/100 µl) of cell suspension was
added with 1 µl fluorescein isothiocyanate (FITC)-conjugated
annexin-V and 2.5 µl propidium iodide (PI; 250 µg/ml).  After
10-min incubation on ice, the cells were measured immedi-
ately.
Western blotting
Aliquots (20 µg) of protein extracts from treated and un-
treated HeLa cells were separated on 12% SDS-
polyacrylamide gels.  After electrophoresis, the proteins
were blotted onto polyvinylidene difluoride membranes.  The
membranes were blocked with 5% non-fat milk in PBS plus
0.1% Tween-20, then incubated with primary antibodies for
p53, E6, E6-AP, Bcl-2 and Bax (BD Biosciences, San Jose,
CA, USA) diluted at 1:1000, and detected with horseradish
peroxidase-conjugated antibodies.  Protein band were
detected by ECL system (Amersham Biosciences, Pis-
cataway, NJ, USA).  The membranes were re-probed with β-
actin as an internal control.  Relative band intensities were
determined by quantitation of each band with an image
analyzer (Alpha-InnoTech, Avery Dennison, CA, USA).
Immunostaining
HeLa cells were fixed on slides and permeabilized with
Triton X-100 for 20 min at 4°C and blocked with 2% FBS in
PBS for 2 h at 37°C.  After washing with PBS, the cells were
incubated with anti-p53 antibody (BD Biosciences) overnight
at a dilution of 1:250 at 4°C.  Following incubation, the slides
were washed and incubated with FITC-conjugated secondary
antibody.  After washing, the slides were visualized with
fluorescence microscope (Leica).
Results
Effect of eurycomanone on cell viability
Eurycomanone significantly reduced the viability and
proliferation of cancer cells (CaOv-3, HeLa, HepG2, HM3KO
and MCF-7) in a concentration-dependent manner (Figure 2).
The IC50 values of eurycomanone on cancer cell lines were
found around 5-10 µM with the IC50 on HeLa cells was the
lowest.    Eurycomanone was also found to be relatively non-
                                                                                                                                                                                         Eurycomanone Induces p53 and Apoptosis
 2008 MedUnion Press − http://www.mupnet.com                                                                                                  111
Figure 2: Cytotoxic effect of eurycomanone on cancer cells.
Treatment of eurycomanone on cancerous cells (CaOv-3, HeLa,
HepG2, HM3KO and MCF-7) significantly reduced the number of
viable cell.  It was relatively non-toxic against non-cancerous cells
(MDBK, Vero).  Results were represented as means of at least three
independent experiments.
toxic to normal cells (MDBK and Vero).  These findings
suggested the potential of eurycomanone as anti-cancer
agent.
Eurycomanone-induced apoptotic cell death
The mode of killing that is induced by most anti-cancer
agents is by apoptotic cell death.  The anti-proliferative
activity shown by eurycomanone could be possibly due to
the induction of apoptosis.  To determine the mode of growth
inhibition in HeLa cells induced by eurycomanone, TUNEL
assay and nuclear staining with Hoechst 33258 were carried
out.  HeLa cells were treated with 5 µM eurycomanone for 24
or 72 h.  Tamoxifen was used as positive control while the
negative control was treated with DMSO.  After treated with
eurycomanone for 24 h, HeLa cells showed active apoptosis
and the fragmented DNA were labeled with fluorescence in
the nuclei by TUNEL assay (Figure 3C).  At 72 h, more
fluorescence was detected, indicating that more cells were
undergoing apoptosis (Figure 3D).  The positive control of
tamoxifen displayed similar nuclear fluorescence, indicating
TUNEL-positive apoptotic cells (Figure 3E and 3F).  In HeLa
cells treated with DMSO as negative control, no fluorescence
was detected in the nuclei, due to the absence of fragmented
DNA (Figure 3B).  This result was also displayed from
untreated HeLa cells (Figure 3A).  The cell undergoing
apoptosis display a profound destruction of the nucleus that
results in the formation of nuclear blebs containing DNA.
Staining of apoptotic cells with a fluorescent DNA-binding
dye allows for easy detection of this phenomenon [31].  The
morphology of apoptotic cells, including chromatin conden-
sation and formation of apoptotic bodies, can be determined
after staining with Hoechst 33258 that binds at specific sites
of double-stranded DNA and displays a green fluorescence.
Hoechst 33258 stains both healthy and apoptotic cells,
however, healthy cells will stain homogenously while
apoptotic cells will stain brightly [32].  Staining with Hoechst
33258 on the HeLa cells treated with eurycomanone for 24 h
showed intense fluorescence in the nuclei (Figure 4B),
thereby indicating chromatin condensation.  At 72 h, HeLa
cells furthermore exhibited apoptotic bodies (Figure 4C).
Next, flow cytometry analysis was used to quantify eury-
comanone-induced apoptotic cells by measuring the exter-
nalization of phosphatidylserine (PS).   In many cell types, in-
Figure 3: TUNEL assay of HeLa cells.  In untreated HeLa cells (A)
or HeLa cells treated with DMSO (B), no obvious fluorescence was
detected in the nuclei, as the cells did not exhibit significant DNA
fragmentation.  HeLa cells treated with eurycomanone at 24 h (C) or
72 h (D), as well as HeLa cells treated with tamoxifen at 24 h (E) or
72 h (F) showed fluorescence in the nuclear regions, indicating
occurrence of DNA fragmentation.  The fluorescence became more
intense with longer treatment duration.
duction of apoptosis is associated with plasma membrane
changes where PS is translocated from the inner layer of
plasma membrane to the outer leaflet [33].  PS is normally
restricted to the inner-membrane leaflet, however dying cells
expose these phospholipids as it is one of the key signals for
phagocyte recognition [34].  PS is maintained in the inner
layer of the plasma membrane by the action of an ATP-
dependent PS flippase.  The flippase is inactivated by
caspases, and a scramblase is activated, leading to redis-
tribution of PS to the outer leaflet of plasma membrane [34].
The externalization of PS can be assessed by measuring the
binding of FITC-conjugated annexin-V to cells by flow
cytometry.  A typical cytogram is shown where cells stained
negative for both annexin-V and PI (PS-/PI-) are live cells as
shown in the lower left quadrant (R3).  Annexin-V positive
and PI-negative (PS+/PI-) stained cells undergo early stages
of apoptosis where the plasma membrane are still intact and
exclude PI (lower right quadrant, R4).  In late stages of
apoptosis, dying cells can no longer exclude PI and the
upper right region (R2) displays both annexinV-positive and
PI-positive (PS+/PI+) cells.  PI positive and annexinV-negative
(PS-/PI+) stained cells in the upper left region (R1) are
necrotic cells.  Our data confirms that eurycomanone was
capable of inducing cell death in HeLa cells (Figure 5A).  In
this experiment, the concentration of eurycomanone used for
treating HeLa cells was 5 µM (IC50 of 3-day treatment was 5.0
± 0.2 µM).  As shown in Figure 5B, the background level of
apoptosis in HeLa cells was 15.51 ± 0.28 % and the back-
ground level of necrosis was 5.64 ± 0.17 %.  After exposure
with eurycomanone, the level of apoptotic cells was in-
creased to 20.9% at 24 h and 28.1% at 48 h, thus indicating
that eurycomanone induced apoptosis in HeLa cells.  After
48 h, there was no increasing of apoptotic level.  The cells in
the secondary necrosis stage were found to increase to
9.78% at 24 h, 14.71% at 48 h and 25.72% after 72 h.  These
results suggested that treatment of eurycomanone on HeLa
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Figure 4: Nuclear staining of HeLa cells
with Hoechst 33258.  Cells were treated
with eurycomanone compare to the
untreated control.  There was no fluores-
cence detected from untreated cells (A),
while HeLa cells treated with eurycoma-
none showed intense fluorescence in the
nuclei at 24 h (B) and even the presence of
nuclear blebs at 72 h (C).
Figure 5: Flow cytometric analysis of
HeLa cells.  A, Flow cytograms of
untreated HeLa cells and HeLa cells
treated with 5 µM of eurycomanone for 24
h, 48 h and 72 h.  Treatment with euryco-
manone resulted a significant increase of
cell death.  Cells in the R1 quadrant were
necrotic cells, R2 quadrant were late stage
apoptotic cells, R4 quadrant were early
apoptotic cells, and the cells in the R3
quadrant were live cells.  B, Results were
represented as means ± SEM of at least
three independent experiments.
Figure 6: Western blot analysis of p53, E6, E6-AP, Bax and Bcl-2
levels in HeLa cells.  HeLa cells were treated with 5 µM eurycoma-
none for indicated times.  p53 protein expression increased after
treatment and followed by increasing of Bax and decreasing of Bcl-
2 level.  However, E6 and E6-AP were still at basal level.  β-actin
was used as the internal control to confirm equal sample loading.
cells induced apoptosis and the apoptotic cells with no
phagocyte surrounding them then entered to secondary
necrotic stage.
Eurycomanone-induced p53 and Bax up-regulation
p53 was the first tumor suppressor gene linked to apopto-
sis.  In most human cancers, p53 does not function correctly,
and indeed, mutations in p53 have been found in nearly all
tumor types and are estimated to contribute to around 50%
of all cancers.  p53 plays an important role in normal cell
proliferation by controlling cell cycle progression and
inducing apoptosis [35].  The activation of p53 can result in
cell cycle arrest, presumably to allow DNA repair to occur
before replication or mitosis.  p53 activation can also result
in apoptosis, as means of eliminating irreparable damaged
cells [36].  Following eurycomanone treatment, it was found
that the p53 level significantly increased.  After 3 h treatment,
the level of p53 was increased by 55%.  The increasing level
reached by 67% after 12 h and maintained at high level
throughout the experiment (Figure 6).  This result was
confirmed by immunostaining method that demonstrated
qualitatively the increasing level of p53 protein expression
(Figure 7A-7C).  However, E6 and E6-AP were kept at the
basal levels, suggesting that eurycomanone induced apop-
tosis by up-regulating p53 protein without affected E6 and
E6-AP in HeLa cells (Figure 6).
Bax and Bcl-2 are downstream targets of p53.  In this
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Figure 7: Immunostaining of p53 in
untreated HeLa cells (A) and HeLa cells
treated with 5 µM eurycomanone for 12 h
(B) or 24 h (C).  Immunostaining of Bax in
untreated HeLa cells (D) and HeLa cells
treated with 5 µM eurycomanone for 12 h
(E) or 24 h (F).  The intensities of im-
munofluorescense of both p53 and Bax
were increased in eurycomanone-treated
HeLa cells.
study, up-regulation of p53 was followed by the increasing of
pro-apoptotic Bax protein expression and decreasing of anti-
apoptotic protein Bcl-2 (Figure 6).  The immunostaining
assay of Bax confirmed the increasing level of Bax in
eurycomanone-treated cells (Figure 7D-7F).
Discussion
Plants are a valuable source of new natural products.
Despite of the availability of different approaches for the
discovery of novel therapeutic agents, natural products still
remain one of the best reservoirs for new molecules [37].
Natural plant products play an important role in chemother-
apy, having contributed considerably to approximately 60
available cancer chemotherapeutic drugs [38].  The need to
develop more effective anti-tumor drugs has prompted
investigators to explore new sources of pharmacologically
active compounds, especially from natural products.
Eurycomanone found in E. longifolia is one of the novel
compounds with promising potencies to be developed as a
new chemotherapeutic agent.  In this study, it was found that
eurycomanone exerted anti-proliferative activity in HeLa
cells with an IC50 value of 5.0 ± 0.2 µM and apoptosis was the
mode of death observed in these cells.  Previous study of
eurycomanone on MCF-7 cells also showed the apoptotic
effect [27].  This fact increases evidence that chemothera-
peutic agents induce cancer cell death through the mecha-
nism of apoptosis [39].  Additionally, eurycomanone also
showed the ability to act as a cytoselective anti-cancer agent,
because eurycomanone was relatively non-toxic towards
non-cancerous MDBK and Vero cells.  The previous study
also showed the minimum effect of eurycomanone on non-
cancerous breast cells (MCF-10A)[27].
Based on the result of TUNEL assay, it was found that
treatment with eurycomanone induced DNA fragmentation in
HeLa cells.  Internucleosomal DNA fragmentation is the
primary biochemical characteristic to indicate an early event
of apoptosis and it represents a point of no return from the
path to cell death [40].  This is due to no more new cellular
protein will be synthesized for cell survival.  In further
analysis using Western blotting, it was found that the
fundamental event that occurred when HeLa cells were
treated with eurycomanone was a marked increase in the
level of p53 tumor suppressor protein.  The present study
showed that p53 was increased 3 h after eurycomanone
treatment and maintained at a higher level throughout the
experiment.
p53 is an extremely efficient inhibitor of cell growth, in-
ducing cell cycle arrest and/or apoptotic cell death, depend-
ing on cell type and environment.  Therefore, regulation of
p53 activity is critical to allow normal cell division.  Tumor-
suppressive function of p53 must be dampened sufficiently
to allow normal growth and development.  There are many
mechanisms through which p53 is regulated.  The major
mechanisms include regulation of p53 protein levels, control
of the localization of p53 protein and modulation of the
activity of p53, particularly its ability to function as a se-
quence-specific transcription factor [36,41].  The incresing
level of p53 in eurycomanone-treated HeLa cells could be
possibly due to the increasing of p53 stability.  The half-life
of p53 was increased, because the p53 protein was found at
an elevated level and maintained at high levels throughout
the experiment.  This is consistent with the previous study
that p53 is a short-lived protein with a half-life of ~5-20 min
[42], however, following the exposure to DNA damage, the
half-life of p53 protein was increases by several folds [43].
Eurycomanone is a cytotoxic agent that might cause DNA
damage in cancer cells.  The DNA damages could be recog-
nized by p53, therefore the p53 level was increased and
apoptosis was induced.  The previous report stated that
activation of p53 could be invoked by as little as one DNA
double-stranded break [44].  This DNA damage could induce
dramatically increase of p53 stability as the signal could be
amplified in the cells.  Previous studies also reported that
apoptosis in HeLa cells induced by xanthorrhizol [45],
staurosporin [46], apigenin [47], vitamin C [48], carboplatin
[49] and cisplatin [50] involved the increasing level of p53.
The increasing level of p53 may play an important role in
increasing the susceptibility of cells to undergo apoptosis.
Some reports stated that loss of p53 increased chemoresis-
tance [51-53].  The study conducted by Attardi and Jacks
[54] showed that cells lacking p53 became resistant to DNA
damage, failing to arrest cell cycle or undergo apoptosis.
Treatment of eurycomanone resulted in increasing apoptotic
cell death, which could be explained by the high level of p53.
p53 in HPV-positive cancer cells was bound by HPV E6
protein, which stimulated p53 degradation in vitro through
the ubiquitin pathway [42].  In vitro analysis of the E6-p53
interaction revealed a cellular protein E6-AP that facilitated
the complex formation of E6 with p53.  Subsequent studies
revealed that the complex of E6 and E6-AP functioned as an
ubiquitin-protein ligase in the ubiquitination and subsequent
degradation of p53 [56,57].  In this study, we found that the
p53 level in eurycomanone-treated HeLa cells was signifi-
cantly increased, however, the E6 and E6-AP levels were
unchanged throughout the experiment.  The effect of eury-
comanone on HeLa cells was compared to xanthorrhizol
which exerted cytotoxicity in HeLa cells by increasing p53
and pro-apoptotic protein Bax without any effect on E6
protein [45].
In our study, the up-regulation of p53 was followed by the
increasing of pro-apoptotic protein Bax and decreasing of
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anti-apoptotic protein Bcl-2 expression.  p53 can transcrip-
tionally repress the Bcl-2 expression and stimulate the Bax
expression [58].  Thus, the effect of p53 on eurycomanone-
induced apoptosis may be mediated, in part, through its
effect on the expression of Bcl-2 and Bax.  In the clinical
study of cervical squamous cell carcinoma treated by
radiotherapy [59], the high expression of Bax was associated
with good survival, while Bcl-2 expression was associated
with poor survival.
In contrast to many other human tumor forms, most HPV-
positive cervical cancer cells possess wild-type p53.  p53
gene mutation in these cells was infrequent.  In mutant-
specific p53 analysis of cervical cancer tissues, only 12 out
of 230 samples studied were found to be positive [60].
Therefore, the finding that apoptosis induced by eurycoma-
none through a p53-mediated pathway leads to a good track
in developing eurycomanone in treatment of cervical cancer.
In conclusion, eurycomanone exerted anti-cancer activity
through inducing cancer cell apoptosis.  The induction of
apoptosis was caused by the up-regulation of p53.  However,
the E6 and E6-AP was not affected.  The downstream effects
of the p53 up-regulation included increasing of Bax level and
decreasing of Bcl-2 expression.  Therefore, it was suggested
that eurycomanone could be further investigated as a new
alternative chemotherapeutic agent for human cervical
carcinoma and other cancer that expressed the wild-type p53.
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